This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Why Atossa Genetics (ATOS) Stock Is Up Today

NEW YORK (TheStreet) -- Atossa Genetics (ATOS - Get Report) stock surged on Thursday after the Board of Directors approved a poison pill provision. The adoption of the stockholder rights agreement is designed to deter "coercive, unfair, or inadequate takeovers and other abusive tactics," the company said in a statement. 

The developer of breast health solutions said the agreement would not prevent takeovers at a full and fair price, but would encourage any potential acquirers to first negotiate with the Board. 

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Under the terms of the agreement, the rights agent will distribute to stockholders a dividend distribution of one preferred stock purchase right for each share of common stock held at the close of business May 26. Rights will be exercisable if a person becomes an "acquiring person" by acquiring ownership of 15% or more of common stock or if a person commences a tender which would result in that person becoming an "acquiring person."

Must Read: Why Semtech Corporation (SMTC) Stock Is Up Today

Rights will expire after a decade, unless redeemed or exchanged. 

By early afternoon, shares of the nano-cap had soared 75.5% to $2.18. Trading volume of 2.8 million shares was more than 18 times its three-month daily average. 

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ATOS $0.28 -13.69%
AAPL $92.72 -0.56%
FB $119.49 1.43%
GOOG $711.12 1.38%
TSLA $214.93 1.61%


Chart of I:DJI
DOW 17,740.63 +79.92 0.45%
S&P 500 2,057.14 +6.51 0.32%
NASDAQ 4,736.1550 +19.0610 0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs